Deadline day approaches for Israel’s market entry hopefuls

By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com Majority of orphan drug manufacturers do not currently view Israel as an early launch opportunity. However, universal reimbursed access to high quality healthcare which is at par with Western European countries, combined with the expansion of the prenatal and new-born screening programmes[1] that have considerably improved diagnosis rates is…